晨光生物(300138.SZ):完成註冊2家子公司
格隆匯11月11日丨晨光生物(300138.SZ)公佈,為實現建設世界天然提取物產業基地的發展戰略目標,加快產業佈局,公司計劃投資1.27億元在貴陽市經濟開發區建設“天然植物有效成分超臨界萃取項目”,並新設子公司貴陽晨光生物科技有限公司具體負責該項目的籌建及運營。
為積極佈局中藥提取領域,為第三步大健康產業做準備,公司擬與北京華醫神農醫藥科技有限公司及李衞民、朱賀年合作建立藥物研發公司(河北晨光神農醫藥科技有限公司),在藥物研究與技術開發、新藥研發、健康產品研發、醫療器械研發、診斷試劑與技術研發等方面加強合作。
董事會審議通過後,籌備組積極開展工作,並於近日完成了上述新設立子公司的註冊,分別取得了貴陽市工商行政管理局貴陽國家經濟技術開發區分局和邯鄲經濟技術開發區行政審批局核發的營業執照。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.